Igor has over two decades of hands-on oncology drug development experience, including successful regulatory IND and NDA/BLA filings across several drug classes. Prior to joining Celcuity, Igor worked for MEI Pharma, an oncology-focused biopharmaceutical company, where he was the vice president (VP) of clinical development. MEI’s pipeline included zandelisib, an oral PI3K-delta inhibitor. He had previously served as the VP of clinical science at Iovance Biotherapeutics, as a global clinical leader at Bayer Pharmaceuticals, and as a senior medical director at Daiichi-Sankyo, a global pharmaceutical company. At Bayer, his responsibilities included leadership of the global clinical development team for Aliqopa®, a pan-PI3K inhibitor approved by the FDA for treatment of patients with follicular lymphoma. Prior to joining industry, he was a practicing clinician treating a broad range of tumor types in adults and children. Igor received his medical training at Omsk State Medical Academy with specialty training in clinical immunology at Chelyabinsk State Medical Academy.
Igor Gorbatchevsky, MD
